QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
NASDAQ:BLRX

BioLineRx (BLRX) Stock Price, News & Analysis

$1.10
-0.01 (-0.90%)
(As of 10:15 AM ET)
Today's Range
$1.10
$1.13
50-Day Range
$1.03
$1.39
52-Week Range
$0.81
$2.53
Volume
57,092 shs
Average Volume
319,122 shs
Market Capitalization
$79.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

BioLineRx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,791.9% Upside
$21.00 Price Target
Short Interest
Healthy
0.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of BioLineRx in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.98) to ($0.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars

Medical Sector

618th out of 939 stocks

Pharmaceutical Preparations Industry

287th out of 431 stocks

BLRX stock logo

About BioLineRx Stock (NASDAQ:BLRX)

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

BLRX Stock Price History

BLRX Stock News Headlines

BioLineRx (NASDAQ:BLRX) Upgraded by StockNews.com to "Sell"
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
BLRX: First Aphexda Sales Recognized
BioLineRx's (BLRX) "Buy" Rating Reaffirmed at HC Wainwright
BioLineRx (BLRX) Scheduled to Post Earnings on Tuesday
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
BLRX Mar 2024 1.000 call
BLRX: Poster Presentations
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
BLRX May 2024 1.000 put
BioLineRx: Still A Buy, With Some Questions
BLRX: A Series of Fortunate Events
biolinerx Q3 2023 Earnings Preview
See More Headlines
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BLRX
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+1,791.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.83 per share

Miscellaneous

Free Float
71,642,000
Market Cap
$80.41 million
Optionable
Optionable
Beta
1.40
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Philip A. Serlin CPA (Age 64)
    M.B.A., CPA, MBA, Chief Executive Officer
    Comp: $635k
  • Ms. Mali Zeevi CPA (Age 48)
    CPA, Chief Financial Officer
    Comp: $380k
  • Dr. Ella Sorani (Age 56)
    Chief Development Officer
    Comp: $457k
  • Ms. Holly W. May M.B.A. (Age 62)
    President of BioLineRx USA
    Comp: $328k
  • Mr. John Lacey
    Head of Corporate Communications & Investor Relations
  • Mr. Adam Janoff Esq.
    General Counsel & Head of Compliance
  • Ms. Tsipi Keren-Lehrer B.Sc.
    L.L.B., Head of BD & Strategic Advisor
  • Mr. Raziel Fried
    Treasurer & Budgetary Control Director

BLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioLineRx stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLRX shares.
View BLRX analyst ratings
or view top-rated stocks.

What is BioLineRx's stock price target for 2024?

1 brokers have issued 1-year price objectives for BioLineRx's stock. Their BLRX share price targets range from $21.00 to $21.00. On average, they anticipate the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 1,791.9% from the stock's current price.
View analysts price targets for BLRX
or view top-rated stocks among Wall Street analysts.

How have BLRX shares performed in 2024?

BioLineRx's stock was trading at $1.57 on January 1st, 2024. Since then, BLRX shares have decreased by 29.3% and is now trading at $1.11.
View the best growth stocks for 2024 here
.

Are investors shorting BioLineRx?

BioLineRx saw a increase in short interest in March. As of March 15th, there was short interest totaling 324,700 shares, an increase of 76.6% from the February 29th total of 183,900 shares. Based on an average daily volume of 316,300 shares, the short-interest ratio is presently 1.0 days.
View BioLineRx's Short Interest
.

When is BioLineRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our BLRX earnings forecast
.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings data on Tuesday, March, 26th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The biotechnology company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same quarter in the prior year, the firm earned ($0.09) EPS.

What other stocks do shareholders of BioLineRx own?
Who are BioLineRx's major shareholders?

BioLineRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include PVG Asset Management Corp (0.09%), Envestnet Asset Management Inc. (0.06%), NorthRock Partners LLC (0.02%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners